Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Venous thromboembolism is not associated with plasmin(ogen): reevaluating plasmin and mechanisms that degrade fibrin. Local targets link to admitted publications; unresolved targets remain external evidence.
Fibrinolysis and the control of blood coagulation
10.1016/j.blre.2014.09.003 · 2015 · External reference
Plasminogen: an enigmatic zymogen
10.1182/blood.2020008951 · 2021 · External reference
Plasminogen deficiency
10.1111/j.1365-2516.2008.01825.x · 2008 · External reference
Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction
10.1101/gad.9.7.794 · 1995 · External reference
Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency
10.1016/s0092-8674(00)81390-2 · 1996 · External reference
Bleeding related to disturbed fibrinolysis
10.1111/bjh.14255 · 2016 · External reference
The effect of epsilon aminocaproic acid on the blood loss after retropubic prostatectomy
10.1111/j.1464-410x.1966.tb09717.x · 1966 · External reference
Aminocaproic acid in the control of haemorrhage after prostatectomy. A controlled trial
10.1016/s0140-6736(66)90051-1 · 1966 · External reference
Tranexamic acid evidence and controversies: an illustrated review
10.1002/rth2.12546 · 2021 · External reference
Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(17)30638-4 · 2017 · External reference
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
10.1016/s0140-6736(10)60835-5 · 2010 · External reference
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial
10.1016/s0140-6736(19)32233-0 · 2019 · External reference
Tranexamica acid in patients undergoing coronary-artery surgery
10.1056/nejmoa1606424 · 2017 · External reference
Tranexamic acid in patients undergoing noncardiac surgery
10.1056/nejmoa2201171 · 2022 · External reference
Tranexamic acid during prehospital transport in patients at risk for hemorrhage after injury: a double-blind, placebo-controlled, randomized clinical trial
2020 · External reference
Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis
10.1182/blood-2004-08-3253 · 2005 · External reference
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1
10.1182/blood-2010-02-267740 · 2010 · External reference
Releasing the brakes on the fibrinolytic system in pulmonary emboli: unique effects of plasminogen activation and α2-antiplasmin inactivation
10.1161/circulationaha.116.024421 · 2017 · External reference
Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of α2-antiplasmin
10.1182/blood.2019000049 · 2019 · External reference
Alpha2-antiplasmin plays a significant role in acute pulmonary embolism
10.1046/j.1538-7836.2003.00252.x · 2003 · External reference
The effect of the fibrinolytic inhibitor epsilon-aminocaproic acid on the incidence of deep-vein thrombosis after prostatectomy
10.1002/bjs.1800590706 · 1972 · External reference
Aminocaproic acid in the control of haemorrhage afterprostatectomy. Safety of aminocaproic acid–a controlled trial
10.1016/s0140-6736(66)90052-3 · 1966 · External reference
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial
10.1016/s0140-6736(18)31033-x · 2018 · External reference
Hospital policy of tranexamic acid to reduce transfusion in major noncardiac surgery
10.1056/nejmoa2515820 · 2026 · External reference
Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women
10.1016/j.ajog.2020.11.035 · 2021 · External reference
Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia
10.1182/bloodadvances.2022008255 · 2023 · External reference
Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF
10.1182/bloodadvances.2025017046 · 2025 · External reference
Evaluation of military use of tranexamic acid and associated thromboembolic events
10.1001/jamasurg.2017.3821 · 2018 · External reference
TXA (tranexamic acid) risk evaluation in combat casualties (TRECC)
10.1136/tsaco-2019-000353 · 2020 · External reference
Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism
10.1097/ta.0000000000002061 · 2019 · External reference
Oral tranexamic acid and thrombosis risk in women
10.1016/j.eclinm.2021.100882 · 2021 · External reference
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(20)30848-5 · 2020 · External reference
Plasminogen activation and plasmin activity are not necessary to prevent venous thrombosis/thromboembolism
10.1182/blood.2025028680 · 2025 · External reference
Frequency of venous thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air Traveller's Thrombosis (NZATT) study
10.1016/s0140-6736(03)15097-0 · 2003 · External reference
Degradation of cross-linked fibrin by human leukocyte proteases
1986 · External reference
Influence of plasminogen deficiency on the contribution of polymorphonuclear leucocytes to fibrin/ogenolysis: studies in plasminogen knock-out mice
10.1055/s-0037-1613306 · 2002 · External reference
Elastase of U-937 monocytelike cells. Comparisons with elastases derived from human monocytes and neutrophils and murine macrophagelike cells
10.1172/jci110462 · 1982 · External reference
Role of neutrophil membrane proteases in fibrin degradation
10.1097/00001721-199512000-00001 · 1995 · External reference
Human homozygous type I plasminogen deficiency and ligneous conjunctivitis
10.1111/j.1699-0463.1999.tb01527.x · 1999 · External reference
Neutrophil elastase-derived fibrin degradation products indicate presence of abdominal aortic aneurysms and correlate with intraluminal thrombus volume
10.1160/th17-05-0348 · 2018 · External reference
Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity
10.1084/jem.193.7.793 · 2001 · External reference
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
10.1111/jth.14768 · 2020 · External reference
COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity
10.1161/atvbaha.120.315338 · 2021 · External reference
A critical role for plasminogen in inflammation
10.1084/jem.20191865 · 2020 · External reference
Complement activation in arterial and venous thrombosis is mediated by plasmin
10.1016/j.ebiom.2016.02.011 · 2016 · External reference
Plasminogen as a ribonucleoprotein: regulatory small RNA cargo modulates fibrinolysis and inflammation
10.1182/blood.2025028959 · 2025 · External reference
